TMVA, a novel GPIb-binding protein, significantly prevents platelet microthrombi formation and prolongs discordant cardiac xenograft survival.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology; D006085:Graft Survival / Q000502:physiology*; D006168:Guinea Pigs; D016027:Heart Transplantation / Q000502:physiology*; D037181:Lectins, C-Type / Q000627:therapeutic use*; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013927:Thrombosis / Q000517:prevention & control*; D014183:Transplantation, Heterologous / Q000502:physiology*; D014757:Viper Venoms / Q000627:therapeutic use*; D014841:von Willebrand Factor / Q000627:therapeutic use*
D037181:Lectins, C-Type; D019038:Platelet Glycoprotein GPIb-IX Complex; C468283:TMVA protein, Trimeresurus mucrosquamatus; D014757:Viper Venoms; D014841:von Willebrand Factor; D000244:Adenosine Diphosphate